- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04799548
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
A Phase II Study of Neoadjuvant Transcatheter Arterial Chemoembolization(TACE)Plus PD-1 Antibody (Tislelizumab) in the Locally Advanced Stomach Adenocarcinoma
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The treatment of advanced gastric cancer has been a significant global health problem. With surgery still the backbone, various clinical trials have shown the benefit of perioperative treatment to gastric cancer patients.
The report of transcatheter arterial chemoembolization (TACE) treatment in gastric cancer is relatively limited, though different case reports have showed its efficacy and safety in advanced gastric cancer. With transarterial infusion chemotherapy, TACE increases the local concentration of chemotherapeutic agents and reduces adverse reaction. With embolization, TACE blocks the blood supply and causes the necrosis of tumors, in this way exposing tumor antigen and promoting tumor immunity. The combination of TACE and PD-1 antibody is expected to further boost tumor immunity.
Meanwhile, Noman et.al. reported hypoxia could upregulate PD-L1 by activating HIF-1alpha. So, embolism may lead to immune evasion of tumors by upregulating PD-L1, but on the other side generate targets for PD-1/PD-L1 therapies.
Based on those knowledges, we designed this phase II, prospective, single-center, single-arm trial to evaluate the efficacy and safety of the combination of neoadjuvant transcatheter arterial chemoembolization (TACE) and PD-1 antibody Tislelizumab in the locally advanced stomach adenocarcinoma. The primary purpose of this study is to evaluate the pathologic complete response (pCR) rate of TACE plus Tislelizumab. The second purpose is to evaluate pathologic response rate (pRR), objective Response Rate (ORR), overall survival (OS) and PFS (progression-free survival) of the patients enrolled in this study.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Xuefei Wang, MD, PhD
- Número de telefone: 86-13917270428
- E-mail: wang.xuefei@zs-hospital.sh.cn
Estude backup de contato
- Nome: Zhaoqing Tang, MD, phD
- Número de telefone: 86-13817125778
- E-mail: tang.zhaoqing@zs-hospital.sh.cn
Locais de estudo
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recrutamento
- Zhongshan Hospital Fudan University
-
Contato:
- Xuefei Wang, MD, PhD
- Número de telefone: 86-13917270428
- E-mail: wang.xuefei@zs-hospital.sh.cn
-
Investigador principal:
- Xuefei Wang, MD, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female, aged 18 to 75 years old;
- KPS score >=80;
- Gastric adenocarcinoma diagnosed pathologically;
- According to endoscopic ultrasonography/enhanced CT/MRI/PET-CT examination and laparoscopic exploration, clinical staging is determined to be cT3/4aN+M0 (according to AJCC TNM 8th edition);
- According to the RECIST1.1 standard, there is at least one evaluable lesion in the abdominal CT/MRI;
- The surgeons participating in this study judged the lesion to be resectable;
- Physical condition allows the surgery;
- The blood routine and biochemical indexes of the subjects met standards within 7 days before enrollment:
- There are no serious concomitant diseases that make the survival time <5 years;
- Female subjects with fertility are not allowed to get pregnant or breastfeeding;
- Be willing and able to comply with the plan and follow-up procedures during the research period.
Exclusion Criteria:
- There are any signs of distant metastasis or local unresectable factors;
- Those who are allergic to contrast agents;
- Those who have received cytotoxic chemotherapy, radiotherapy, immunotherapy or radical surgery for the treatment of this gastric cancer, except for corticosteroids;
- Patients who have active autoimmune diseases or have a history of autoimmune diseases but may relapse;
- Any active malignant tumors within 2 years, except the specific cancers under study in this trial and locally recurring cancers that have been cured (such as resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast cancer);
- There is uncontrollable pleural effusion, pericardial effusion or ascites that requires frequent drainage within 14 days before enrollment;
- Patients with gastrointestinal bleeding within two weeks prior to enrollment, or those with high bleeding risk as judged by the investigators;
- Gastrointestinal perforation and/or fistula occurred within 6 months before enrollment;
- Upper gastrointestinal obstruction or abnormal physiological function or suffering from malabsorption syndrome, which may affect the absorption of drugs;
- Weight loss >=20% within 2 months before enrollment;
- A history of the following lung diseases: interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, etc.;
- There are uncontrollable systemic diseases including diabetes, hypertension, etc.;
- Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis, HIV infection, etc.;
- Untreated patients with chronic hepatitis B or chronic HBV carriers with hepatitis B virus (HBV) DNA exceeding 500 IU/mL, or hepatitis C virus (HCV) RNA positive patients should be excluded;
- Any of the following cardiovascular risk factors (refer to Research Guide)
- Known peripheral nerve disease >=NCI CTCAE Grade 1. However, patients with only the disappearance of the deep tendon reflex (DTR) need not be excluded;
- Moderate or severe renal damage [creatinine clearance equal to or lower than 50 ml/min (calculated according to the Cockroft and Gault equation)], or serum creatinine>ULN;
- People with known dihydropyrimidine dehydrogenase (DPD) deficiency;
- Those who are allergic to any research drug ingredients;
- Have had allogeneic stem cell transplantation or organ transplantation;
- Patients requiring systemic treatment with corticosteroids (dose higher than 10 mg/d of prednisone or equivalent doses of similar drugs) or other immunosuppressive agents <=14 days before enrollment.
- Have received live vaccines within 4 weeks before enrollment. (Remarks: Seasonal flu vaccines are usually inactivated vaccines and are allowed to be used. Vaccines used in the nasal cavity are live vaccines and are not allowed.);
- Have received immunotherapy (such as interleukin, interferon, thymosin, etc.) or any trial treatment within 28 days or 5 half-lives (whichever is shorter, but at least 14 days) before enrollment;
- Palliative radiotherapy was performed within 14 days before enrollment;
- Have received anti-PD-1, anti-PD-L1, anti-PD-L2 or any other specific targeting T cell costimulation or checkpoint pathway antibodies or drug therapy;
- Underwent major surgery within 28 days prior to enrollment, unless the surgery was minimally invasive (for example, central venous catheterization via peripheral venipuncture [PICC]);
- For people with a history of uncontrolled epilepsy, central nervous system disease, or mental disorder, the investigator will determine whether the clinical severity hinders the signing of informed consent or affects the patient's compliance with oral medications;
- There is a potential medical condition or alcohol/drug abuse or dependence that the investigator believes is not conducive to the administration of the study drug or that affects the interpretation of drug toxicity or adverse events.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: neoadjuvant TACE plus Tislelizumab
|
Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy. TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid. SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid.
PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
pathologic complete response (pCR) rate
Prazo: 1 months
|
1 months
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
sobrevida global (OS)
Prazo: 3 anos
|
3 anos
|
sobrevida livre de progressão (PFS)
Prazo: 3 anos
|
3 anos
|
pathologic response rate (pRR)
Prazo: 1 months
|
1 months
|
objective Response Rate (ORR)
Prazo: 1 months
|
1 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Xuefei Wang, MD, phD, Fudan University
Publicações e links úteis
Publicações Gerais
- Su Z, Shu K, Kang M, Wang G. Pathological complete response from oral chemotherapy combined with trans-arterial chemotherapy and embolization in an unresectable gastric cancer patient: A case report. Medicine (Baltimore). 2019 Jun;98(25):e16075. doi: 10.1097/MD.0000000000016075.
- Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol Res. 2017 Jan;5(1):9-16. doi: 10.1158/2326-6066.CIR-16-0103. Epub 2016 Dec 9.
- Wu ZF, Cao QH, Wu XY, Chen C, Xu Z, Li WS, Yao XQ, Liu FK. Regional Arterial Infusion Chemotherapy improves the Pathological Response rate for advanced gastric cancer with Short-term Neoadjuvant Chemotherapy. Sci Rep. 2015 Dec 1;5:17516. doi: 10.1038/srep17516.
- Zhang CW, Zou SC, Shi D, Zhao DJ. Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. World J Gastroenterol. 2004 Oct 15;10(20):3070-2. doi: 10.3748/wjg.v10.i20.3070.
- Friedlander M, Meniawy T, Markman B, Mileshkin L, Harnett P, Millward M, Lundy J, Freimund A, Norris C, Mu S, Wu J, Paton V, Gao B. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019 Sep;20(9):1306-1315. doi: 10.1016/S1470-2045(19)30396-1. Epub 2019 Aug 1.
- Xu J, Bai Y, Xu N, Li E, Wang B, Wang J, Li X, Wang X, Yuan X. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2020 Sep 1;26(17):4542-4550. doi: 10.1158/1078-0432.CCR-19-3561. Epub 2020 Jun 19.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ZSGC-TACiE04
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer Gástrico Avançado
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
Ensaios clínicos em Transcatheter Arterial Chemoembolization
-
Xiamen Cardiovascular Hospital, Xiamen UniversityRecrutamentoInsuficiência cardíaca | Insuficiência mitral | Estenose Mitral | Estenose Mitral com Insuficiência | Falha da biopróteseChina
-
Xiamen Cardiovascular Hospital, Xiamen UniversityRecrutamento
-
University of PatrasDesconhecidoAcesso arterial em angiografia coronária percutânea ou intervençãoGrécia
-
Tianjin Huanhu HospitalRecrutamento
-
Weill Medical College of Cornell UniversitySunnybrook Health Sciences Centre; Columbia University; Duke University; Cedars-Sinai... e outros colaboradoresRecrutamentoDoenças cardíacas | Doença arterial coronária | Enxerto de Revascularização do MiocárdioEstados Unidos, Áustria, Israel, Canadá, Republica da Coréia, Espanha, Suécia, Croácia, Alemanha, Reino Unido, China, Polônia, Itália, Brasil, Tcheca, Índia, Japão, Holanda, Portugal, Sérvia, Cingapura, Taiwan, Austrália, Macedônia do Norte e mais
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health...Ativo, não recrutandoDoenças cardíacas | Doença arterial coronáriaEstados Unidos, Brasil, Canadá, Cingapura, Itália, Alemanha, China, Croácia, Sérvia, Portugal, Áustria, Tcheca, Japão, Republica da Coréia, Holanda, Polônia, Espanha
-
NYU Langone HealthConcluídoHipertensão | HipotensãoEstados Unidos
-
Mayo ClinicConcluídoHipertensão | DiabetesEstados Unidos
-
University Hospital of PatrasConcluídoOclusão da Artéria Radial | Angiografia coronária | Acesso ArterialGrécia
-
Wujin People's HospitalRecrutamentoDoenças cardiovasculares | Doença arterial coronáriaChina